Minireviews
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. May 26, 2021; 13(5): 439-451
Published online May 26, 2021. doi: 10.4252/wjsc.v13.i5.439
Different kinds of stem cells in the development of SARS-CoV-2 treatments
Monica Maribel Mata-Miranda, Miguel Sanchez-Brito, Gustavo Jesus Vazquez-Zapien
Monica Maribel Mata-Miranda, Cell and Tissue Biology Laboratory, Escuela Militar de Medicina, Mexico 11200, Mexico
Miguel Sanchez-Brito, Computational Sciences, TecNM/Technological Institute of Aguascalientes, Aguascalientes 20256, Mexico
Gustavo Jesus Vazquez-Zapien, Embryology Laboratory, Escuela Militar de Medicina, Mexico 11200, Mexico
Author contributions: Mata-Miranda MM and Vazquez-Zapien GJ designed, wrote, and reviewed the paper; Sanchez-Brito M wrote and revised the paper.
Conflict-of-interest statement: Authors declare no conflict of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Gustavo Jesus Vazquez-Zapien, MD, PhD, Doctor, Professor, Embryology Laboratory, Escuela Militar de Medicina, Cerrada de Palomas S/N, Mexico 11200, Mexico. gus1202@hotmail.com
Received: January 16, 2021
Peer-review started: January 16, 2021
First decision: February 14, 2021
Revised: February 27, 2021
Accepted: April 22, 2021
Article in press: April 22, 2021
Published online: May 26, 2021
Processing time: 130 Days and 8.1 Hours
Core Tip

Core Tip: The use of stem cells (SCs) to address the coronavirus disease 2019 (COVID-19) pandemic has been widely studied in various fields; for example, human embryonic SCs and human induced pluripotent SCs have been used to generate functional human cells, tissues, and organoids that are used for modeling COVID-19 and discovering drugs. Mesenchymal SCs and their exosomes have been used in clinical trials to control the severe acute respiratory syndrome coronavirus 2 immune response, showing absorption of pulmonary lesions and clinical improvement.